Last reviewed 2026-04-20 · How we verify

Methyl Proscillaridin A (MEPROSCILLARIN)

Phase 2 active Small molecule

Methyl Proscillaridin A (generic name: MEPROSCILLARIN) is a drug. It is currently in Phase 2 development.

Methyl Proscillaridin A works by inhibiting the sodium/potassium-transporting ATPase subunit alpha-1.

Methyl Proscillaridin A (MEPROSCILLARIN) is a small molecule drug targeting the sodium/potassium-transporting ATPase subunit alpha-1. Its mechanism of action and approved indications are not well-documented, and it is unclear if it is FDA-approved or commercially available. Further research is needed to determine its clinical utility and safety profile. As a result, it is not possible to provide a comprehensive summary of its commercial status or key safety considerations. More information is required to accurately describe this compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MEPROSCILLARIN
Target	Sodium/potassium-transporting ATPase subunit alpha-1
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a pump in your body that helps move sodium and potassium in and out of cells. Methyl Proscillaridin A blocks this pump, which can affect how your body regulates these important minerals. This can have various effects on the body, but the exact impact depends on the specific condition being treated.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Methyl Proscillaridin A CI brief — competitive landscape report
Methyl Proscillaridin A updates RSS · CI watch RSS

Frequently asked questions about Methyl Proscillaridin A

What is Methyl Proscillaridin A?

Methyl Proscillaridin A (MEPROSCILLARIN) is a Small molecule drug.

How does Methyl Proscillaridin A work?

Methyl Proscillaridin A works by inhibiting the sodium/potassium-transporting ATPase subunit alpha-1.

What is the generic name of Methyl Proscillaridin A?

MEPROSCILLARIN is the generic (nonproprietary) name of Methyl Proscillaridin A.

What development phase is Methyl Proscillaridin A in?

Methyl Proscillaridin A is in Phase 2.

What does Methyl Proscillaridin A target?

Methyl Proscillaridin A targets Sodium/potassium-transporting ATPase subunit alpha-1.

Target: All drugs targeting Sodium/potassium-transporting ATPase subunit alpha-1
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing